Ausgabe 2/2017
Inhalt (23 Artikel)
Ionotropic glutamate receptor antagonists and cancer therapy: time to think out of the box?
Mariana P. C. Ribeiro, José B. A. Custódio, Armanda E. Santos
The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer
Hongjing Zang, Weiyuan Wang, Songqing Fan
Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues
Bronwen J. Mayo, Andrea M. Stringer, Joanne M. Bowen, Emma H. Bateman, Dorothy M. Keefe
Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors
Elham Ajorlou, Ahmad Yari Khosroushahi
Clinical research on rare diseases of children: neuroblastoma
Chiara Gerardi, Rita Banzi, Vittorio Bertele’, Silvio Garattini
On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis
Jing Hu, Zhen Zhang, Rui Zheng, Lei Cheng, Mi Yang, Li Li, Baorui Liu, Xiaoping Qian
Research progress of hydroxychloroquine and autophagy inhibitors on cancer
Ting-Ting Shi, Xiao-Xu Yu, Li-Jun Yan, Hong-Tao Xiao
Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells
Jan S. Moreb, Deniz A. Ucar-Bilyeu, Abdullah Khan
Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1)
Muhammad Wasif Saif, Andrew Heaton, Kimberley Lilischkis, James Garner, David M. Brown
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer
Jeffrey R. Infante, Amita Patnaik, Claire F. Verschraegen, Anthony J. Olszanski, Montaser Shaheen, Howard A. Burris, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Scott M. Hynes, Jennifer Leohr, Aimee Bence Lin, Lily Q. Li, Anna McGlothlin, Daphne L. Farrington, Eric H. Westin, Roger B. Cohen
Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205
Hong-Yan Zhang, Feng Liang, Jian-Wei Zhang, Fei Wang, Li Wang, Xi-Gang Kang
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
John Sarantopoulos, Alain C. Mita, Aiwu He, James L. Wade, Chung-Tsen Hsueh, John C. Morris, A. Craig Lockhart, David I. Quinn, Jimmy Hwang, James Mier, Wenping Zhang, Claudine Wack, Jian Yin, Pierre-François Clot, Olivier Rixe
Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
Angelica L. Quartino, Hanbin Li, Jin Y. Jin, D. Russell Wada, Mark C. Benyunes, Virginia McNally, Lucia Viganò, Ihsan Nijem, Bert L. Lum, Amit Garg
Myeloprotective effects of C-type natriuretic peptide on cisplatin-induced bone marrow granulocytopenia in mice
Masahiro Zenitani, Takashi Nojiri, Toru Kimura, Hiroshi Hosoda, Koichi Miura, Jun Hino, Kengo Nakahata, Shuichiro Uehara, Mikiya Miyazato, Takaharu Oue, Hiroomi Okuyama, Kenji Kangawa
The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy
Jianli Chen, Charalambos Solomides, Fiona Simpkins, Henry Simpkins
Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer
Samer Tabchi, Normand Blais, Marie-Pierre Campeau, Mustapha Tehfe
Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents
Manikandan Alagumuthu, Sivakumar Arumugam
Modulation of cyclophosphamide-induced cardiotoxicity by methyl palmitate
Dina S. El-Agamy, Mohamed A. Elkablawy, Hany M. Abo-Haded
Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways
Hannes Liebig, Georg Günther, Marlen Kolb, Christian Mozet, Andreas Boehm, Andreas Dietz, Gunnar Wichmann
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
Ghassan K. Abou-Alfa, Chia-Jui Yen, Chih-Hung Hsu, Joseph O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Bolorsukh Gansukh, Serge K. Lyashchenko, Jennifer Ma, Peter Wan, Yu-Yun Shao, Zhong-Zhe Lin, Catherine Frenette, Bert O’Neil, Lawrence Schwartz, Peter M. Smith-Jones, Toshihiko Ohtomo, Takayoshi Tanaka, Hideo Morikawa, Yuko Maki, Norihisa Ohishi, Ya-Chi Chen, Tamara Agajanov, Frederic Boisserie, Laura Di Laurenzio, Ray Lee, Steven M. Larson, Ann-Lii Cheng, Jorge A. Carrasquilo
Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report
Janet K. Coller, Joanne M. Bowen, Imogen A. Ball, Hannah R. Wardill, Ysabella Z. A. van Sebille, Romany L. Stansborough, Zenab Lightwala, Anthony Wignall, Joseph Shirren, Kate Secombe, Rachel J. Gibson
Comment to: GSTP1, GSTM1 and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis
Sarah Cargnin, Salvatore Terrazzino
Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect?
Ian Joseph Cohen